Enter an email address below to share the provider's page with someone you know.
Dr. David Browning is a board-certified ophthalmologist who focuses on vitreoretinal diseases and surgery, macular degeneration, and the retina in the Charlotte, NC and Concord, NC areas. He is board-certified by the American Board of Ophthalmology. He has authored and co-authored more than 135 papers in peer-reviewed journals and has written and edited three textbooks.
Dr. Browning practices in our SouthPark (6035 Fairview
Road, Charlotte, NC) and Concord (645 Amalia Street NE, Concord,
NC) offices. To make an appointment with him, call 704-295-3000. You can also
request an appointment online or through myCEENTAchart.
UndergraduateHarvard University, 1975
PhD and MedicalDuke University, 1980 and 1981, respectively
InternshipDuke University Medical Center, 1982
ResidencyOphthalmology, Duke Eye Center, 1985
FellowshipVitreoretinal diseases, Bascom Palmer Eye Institute, University of Miami, 1986
Board Certified by:- American Board of Ophthalmology
- American Board of Ophthalmology, Examiner and Mentor Examiner
- American Academy of Ophthalmology, Fellow
- American Ophthalmological Society
- Executive Editor of the American Journal of Ophthalmology and Editorial Board member of Retina
Charlotte Magazine Top Doctors, 2021
Dr. Browning has served at the Lion’s Eye Clinic of Charlotte for 35 years.
Dr. Browning has given continuing education talks including:
"Melanoma, Mecklenburg... and More" "OCT Omnibus - Cases That Will Make You Sharper in Clinic" "Screening for Hydroxychloroquine Retinopathy in 2018" "Retinal Cases with a Point”
Dr. Browning has authored and co-authored more than 135 papers in peer-reviewed journals including: Quantifying Conflict of Interest in the Choice of Anti-VEGF Agents
Browning DJ, Greenberg PB. Clinical Ophthalmology 2021:15 1403–1408
He is the author and editor of three textbooks including: Hydroxychloroquine and Chloroquine Retinopathy, published in 2014.
He has directed/participated in more than 35 clinical research trials and is currently enrolling patients in trials for treatments of diabetic retinopathy and vitreomacular traction syndrome.